Get the Stockscreener App
126.15
2.96%
-3.85
After Hours:
126.11
-0.04
-0.03%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $126.15, with a volume of 10.31M.
It is down -2.96% in the last 24 hours and down -1.86% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$130.00
Open:
$129.89
24h Volume:
10.31M
Relative Volume:
1.80
Market Cap:
$219.56B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.82
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-2.07%
1M Performance:
-1.86%
6M Performance:
-6.93%
1Y Performance:
+7.70%
1-Day Range:
$124.58
$131.49
1-Week Range:
$124.58
$132.03
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.15 | 226.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.01 | 147.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.23 | 137.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.34 | 129.29B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
86.02 | 48.77B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Chicago's Abbott Circles Cancer-Test Maker In Giant Deal Talks - Hoodline
Exact Sciences stock jumps on Abbott Labs acquisition speculation By Investing.com - Investing.com UK
Exact Sciences stock jumps on potential acquisition by Abbott - Investing.com UK
Abbott Labs stock rises on potential Exact Sciences acquisition talks - Investing.com India
Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories - MSN
Exact Sciences shares soar on report Abbott is nearing deal for the company - Investing.com
Is Exact Sciences Getting A Deal? Shares Surge On Rumors. - Investor's Business Daily
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories - Barron's
Abbott Nears Deal for Cancer Test Maker Exact Sciences - Bloomberg.com
Abbott (ABT) Approaches Acquisition of Exact Sciences - GuruFocus
Exact Sciences could be sold to Abbott Laboratories, report says - Wisconsin State Journal
Exact Sciences (EXAS) Shares Surge on Potential Abbott Takeover - GuruFocus
Abbott nears deal to acquire Exact Sciences stock, William Blair reiterates Outperform - Investing.com
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories - MSN
Exact Sciences likely needs to see over $100/share in takeoveranalyst (EXAS:NASDAQ) - Seeking Alpha
Exact Sciences shares skyrocket amid reports of Abbott takeover - MassDevice
Abbott in talks to buy exact sciences as cologuard maker’s shares jump - The Economic Times
Exact Sciences (EXAS) Surges on Potential Abbott Takeover - GuruFocus
Abbott (ABT) Moves Toward Acquiring Exact Sciences - GuruFocus
Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025 - ts2.tech
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports - Reuters
Exact Sciences shares soar on report Abbott is nearing deal for the company By Investing.com - Investing.com South Africa
Abbott weighs takeover of cancer test maker Exact Sciences, Bloomberg says - TipRanks
Exact Sciences jumps on report Abbott nears takeover (EXAS:NASDAQ) - Seeking Alpha
Can Abbott Laboratories (Common Stock) (ABL0) stock sustain margin levelsQuarterly Performance Summary & Risk Controlled Stock Pick Alerts - newser.com
Abbott Laboratories (NYSE:ABT) jumps 3.3% this week, though earnings growth is still tracking behind three-year shareholder returns - Yahoo Finance
Businesses have slowed at making commitments – but Abbott Labs is still planning to build in BG - BG Independent News
AbbVie Stock Falls 4% -- What Investors Need to Know - The Motley Fool
Sentiment analysis tools applied to Abbott LaboratoriesJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Is Abbott Laboratories (Common Stock) (ABL0) stock a top dividend aristocrat candidateWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Assessing Abbott Laboratories (ABT) Valuation Potential After Recent Share Price Momentum - simplywall.st
Will earnings trigger a reversal in Abbott LaboratoriesWatch List & Weekly Breakout Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock benefit from infrastructure billQuarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Abbott Laboratories Stock: The Battle for the $140 Threshold - AD HOC NEWS
Can Abbott Laboratories stock surprise with earnings upsideBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report? - Yahoo Finance
What Does the Market Think About Abbott Laboratories? - Benzinga
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Is Abbott Laboratories stock a buy on dipsMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
New data backs Abbott Aveir dual-chamber leadless pacemaker system - MassDevice
Here’s Why Abbott Laboratories (ABT) Traded Down in Q3 - Insider Monkey
Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
FDA expands urgent baby formula recall to all products made by one manufacturer - TheStreet
Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling - Insider Monkey
Abbott competitor's baby formula recalled after infant botulism outbreak - Crain's Chicago Business
Why pension funds invest in Abbott Laboratories (ABL) stockPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Unnatural Amino Acids Market to Reach US$ 5.03 Billion By 2032 Driven by Advances in Drug Discovery, Biologics and Protein Engineering - GlobeNewswire Inc.
A Look at Abbott Laboratories’s Valuation Following Revenue Growth and Maintained Outlook - Yahoo Finance
How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares - Yahoo Finance
Why Abbott Laboratories (ABL) stock could be next leaderQuarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Will a bounce in Abbott Laboratories offer an exit2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):